Axovant Sciences Ltd. (NYSE:AXON) has been given an average rating of “Buy” by the twelve analysts that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $29.17.
Several equities analysts recently issued reports on the stock. BidaskClub raised shares of Axovant Sciences from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Jefferies Group LLC reissued a “buy” rating and set a $31.00 price target on shares of Axovant Sciences in a report on Tuesday, April 18th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Axovant Sciences in a report on Wednesday, March 22nd. CIBC lifted their price target on shares of Axovant Sciences from $30.00 to $33.00 and gave the company a “neutral” rating in a report on Tuesday, April 18th. Finally, Cowen and Company restated an “outperform” rating and issued a $30.00 price objective on shares of Axovant Sciences in a research report on Wednesday, June 21st.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Norges Bank bought a new position in shares of Axovant Sciences during the fourth quarter worth $508,000. AQR Capital Management LLC bought a new position in shares of Axovant Sciences during the fourth quarter worth $139,000. Woodstock Corp raised its position in shares of Axovant Sciences by 55.0% in the first quarter. Woodstock Corp now owns 35,003 shares of the biotechnology company’s stock worth $523,000 after buying an additional 12,417 shares during the last quarter. Primecap Management Co. CA raised its position in shares of Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock worth $43,011,000 after buying an additional 2,159,428 shares during the last quarter. Finally, Nationwide Fund Advisors raised its position in shares of Axovant Sciences by 70.9% in the first quarter. Nationwide Fund Advisors now owns 83,543 shares of the biotechnology company’s stock worth $1,248,000 after buying an additional 34,654 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.
Shares of Axovant Sciences (NYSE AXON) opened at 23.67 on Tuesday. The company’s 50 day moving average is $22.40 and its 200-day moving average is $17.00. Axovant Sciences has a 12 month low of $11.01 and a 12 month high of $26.49. The company’s market cap is $2.54 billion.
Axovant Sciences (NYSE:AXON) last released its quarterly earnings data on Tuesday, June 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by $0.02. Analysts expect that Axovant Sciences will post ($2.20) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Axovant Sciences Ltd. (NYSE:AXON) Receives Average Rating of “Buy” from Brokerages” was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/07/18/axovant-sciences-ltd-axon-receives-average-recommendation-of-buy-from-brokerages-updated-updated-updated.html.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.